PT - JOURNAL ARTICLE AU - Christina A. Rostad AU - Ann Chahroudi AU - Grace Mantus AU - Stacey A. Lapp AU - Mehgan Teherani AU - Lisa Macoy AU - Bradley S. Rostad AU - Sarah S. Milla AU - Keiko M. Tarquinio AU - Rajit K. Basu AU - Carol Kao AU - W. Matthew Linam AU - Matthew G. Zimmerman AU - Pei-Yong Shi AU - Vineet D. Menachery AU - Matthew E. Oster AU - Sri Edupuganti AU - Evan J. Anderson AU - Mehul Suthar AU - Jens Wrammert AU - Preeti Jaggi TI - Serology in Children with Multisystem Inflammatory Syndrome (MIS-C) associated with COVID-19 AID - 10.1101/2020.07.10.20150755 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.10.20150755 4099 - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20150755.short 4100 - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20150755.full AB - Objectives We aimed to measure SARS-CoV-2 serologic responses in children hospitalized with multisystem inflammatory syndrome (MIS-C) compared to COVID-19, Kawasaki Disease (KD) and other hospitalized pediatric controls.Methods From March 17, 2020 - May 26, 2020, we prospectively identified hospitalized children at Children’s Healthcare of Atlanta with MIS-C (n=10), symptomatic PCR-confirmed COVID-19 (n=10), KD (n=5), and hospitalized controls (n=4). With IRB approval, we obtained prospective and residual blood samples from these children and measured SARS-CoV-2 spike (S) receptor binding domain (RBD) IgM and IgG binding antibodies by quantitative ELISA and SARS-CoV-2 neutralizing antibodies by live-virus focus reduction neutralization assay. We statistically compared the log-transformed antibody titers among groups and performed correlation analyses using linear regression.Results All children with MIS-C had high titers of SARS-CoV-2 RBD IgG antibodies, which correlated strongly with neutralizing antibodies (R2=0.667, P<0.001). Children with MIS-C had significantly higher SARS-CoV-2 RBD IgG antibody titers (geometric mean titer [GMT] 6800, 95%CI 3495-13231) than children with COVID-19 (GMT 626, 95%CI 251-1563, P<0.001), children with KD (GMT 124, 95%CI 91-170, P<0.001) and other hospitalized pediatric controls (GMT 85 [all below assay limit of detection], P<0.001). All children with MIS-C also had detectable RBD IgM antibodies, indicating recent SARS-CoV-2 infection. RBD IgG titers correlated with erythrocyte sedimentation rate (ESR) (R2=0.512, P<0.046) and with hospital and ICU lengths of stay (R2=0.590, P=0.010).Conclusion Quantitative SARS-CoV-2 RBD antibody titers may have a role in establishing the diagnosis of MIS-C, distinguishing it from other similar clinical entities, and stratifying risk for adverse outcomes.Table of Contents Summary Children with MIS-C have high antibody titers to the SARS-CoV-2 spike protein receptor binding domain, which correlate with neutralization, systemic inflammation, and clinical outcomes.What’s Known on This Subject Although the clinical features of a multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 have been recently described, the serologic features of MIS-C are unknown.What This Study Adds In this case series, all hospitalized children with MIS-C had significantly higher SARS-CoV-2 binding and neutralizing antibodies than children with COVID-19 or Kawasaki Disease. SARS-CoV-2 antibodies correlated with metrics of systemic inflammation and clinical outcomes, suggesting diagnostic and prognostic value.Competing Interest StatementDr. Anderson has received personal fees from AbbVie and Pfizer for consulting. Dr. C. Rostad receives royalties unrelated to this manuscript to Emory University from Meissa Vaccines, Inc. Dr. Anderson and Dr. C. Rostad's institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron. The other authors have no conflicts of interest to disclose.Clinical TrialN/AFunding StatementThis work was supported by the Centers for Childhood Immunizations and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University, the Georgia Research Alliance (GRA), and a Synergy Award from Emory University School of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was approved by the IRBs at Children's Healthcare of Atlanta and Emory University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript can be made available upon request.AHAAmerican Heart AssociationANOVAAnalysis of varianceBMIBody mass indexCDCCenters for Disease Control and PreventionCOVID-19Coronavirus disease 2019ELISAEnzyme-linked immunosorbent assayELISPOTEnzyme-linked immune absorbent spotESRErythrocyte sedimentation rateFRNTFocus reduction neutralization titerHFNCHigh-flow nasal cannulaICUIntensive care unitIVIGIntravenous immune globulinKDKawasaki DiseaseLODLimit of detectionLOSLength of stayMIS-CMultisystem inflammatory syndrome in childrenN proteinNucleocapsid proteinNPNasopharyngealRBDReceptor binding domainRT-PCRReal-time polymerase chain reactionS proteinSpike proteinSARS-CoV-2Severe acute respiratory syndrome coronavirus 2